To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in subjects with HER2-positive unresectable locally advanced or metastatic colorectal cancer (CRC).
Subjects voluntarily participate in this study, sign the informed consent form, and have good compliance
Age: 18-75 years (including the boundary when signing the informed consent form)
Eastern Cooperative Oncology Group (ECOG) score: 0-1
Expected survival of more than 3 months
Patients with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
Active inflammatory bowel disease within 28 days prior to first dose
Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies